Rhcg
BRCA1 Mutation
Fox Chase Cancer CenterN/ADormant
D
27/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 12/ 100
- Competitive Position
- 81/ 100
Competitive context
16 Active assets in the BRCA1 Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ovitrelle University Hospital, Ghent | Phase 4 | BB |
Olaparib GBG Forschungs GmbH | Phase 2 | B |
CIS-DIAMMINEDICHLOROPLATINUM II The University of Texas Health Science Center at San Antonio | Phase 3 | B |
Niraparib University of California, San Francisco | Phase 2 | B |
Irinotecan University of California, San Francisco | Phase 2 | B |
View all 25 →
Same molecule, other indications
Rhcg is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →